Andrew Gardner graduated from the University of Leicester with a degree in mathematics, physics and astronomy, before going on to study management science and operations research at Imperial College London. Andrew is very entrepreneurial and for the past 30 years has been working in the leisure industry where he founded and ran Victoria Travel Services and Cruise.co.uk. As the founder and Chairman of cruise.co.uk, he grew the company to be Europe’s largest online cruise retailer with revenues of £120M in 2016. In 2016, Andrew sold the business to a private equity group. Andrew joined the Board in 2017 and brings a wealth on online marketing experience to the Board.
Chief Executive Officer
Robert is originally from Palo Alto and moved to London with his family as a child and has resided permanently in the UK since the 1980s. He has more than 30 years of experience in the natural products industry in the United States, Europe and China. His interest in medicinal plants came about through his personal experience of having been successfully treated for a debilitating chronic disease with traditional Chinese medicine. After this experience he changed careers and became one of the pioneering entrepreneurs in plant-derived healthcare products. Robert has a particular interest in China where he has spent more than 25 years developing commercial and academic collaborations. In December 2013 he was a member of the British business delegation that accompanied David Cameron on his first Trade Mission to China.
Chen Xie PhD
Chief Science Officer (Beijing)
Chen is the co-founder of Phynova’s Chinese subsidiary, BCCL and has over 18 years’ experience in botanic drug and product development. She holds her MSc degree from Peking Union Medical University and her PhD in plant chemistry and bioactivities from King’s College, University of London. Prior to Botanic Century, she worked for IMPLAD, Chinese Academy of Medical Sciences serving as Professor and Head of the Phytochemistry Department. She has successfully led several new drug development programs and has extensive experience in Chinese regulatory affairs.
Gordon is a non executive board member of Swire Pacific, Lenovo, BPL and the China Britain Business Council. Gordon was responsible for establishing McKinsey’s China practice, with the opening of offices in Shanghai and Beijing in 1993 and 1995, respectively. From 1999 to 2004, he served as managing director of McKinsey’s Greater China offices and subsequently led McKinsey Asia. He is still a senior advisor to McKinsey on China related topics.
Luc has nearly 40 years international experience in healthcare industry. He worked 10 years for Schering-Plough in three countries in Europe and then 29 years for Roche, in Pharma, in Diagnostics and Diabetes Care, in 7 countries including Thailand and USA. His last role for Roche was as Global Head of the Operating Divisional Group Roche Diabetes Care, with responsibility for total value chain from Technology and R&D to Operations and Marketing & sales (HC 5500, sales $2.5B).
Rob Beudeker is currently responsible for the investment in start-up companies active in nutrition as Investment Director at DSM Venturing. From 2010 to 2016, he was active as VP Innovation at Human Nutrition and Health at DSM, steering these activities globally from Switzerland. Prior to this, Rob held various functions in R&D (project-, program- and resource management) and New Business Development at DSM, known as Gist-Brocades at the time he joined in 1984. Before this he worked as a post-doc at the University of Texas in Austin in molecular biology.
Rob has a MSc in biology and PhD in microbiology from the University of Groningen in The Netherlands, as well as a MBA from the Universities of Rotterdam and Rochester (NY). In addition, he is a member of the supervisory board at JavaFoods, Phynova, Frontier Nutrition and S-Biomedic. He also works at TiFN (Wageningen, The Netherlands) as Program Director for Health and Nutrition.